A realist evaluation of patients' decisions to deprescribe in the EMPOWER trial

Philippe Martin, Cara Tannenbaum, Philippe Martin, Cara Tannenbaum

Abstract

Background and objectives: Successful mechanisms for engaging patients in the deprescribing process remain unknown but may include: (1) triggering motivation to deprescribe by increasing patients' knowledge and concern about medications; (2) building capacity to taper by augmenting self-efficacy and (3) creating opportunities to discuss and receive support for deprescribing from a healthcare provider. We tested these mechanisms during theEliminating Medications through Patient Ownership of End Results (EMPOWER) () trial and investigated the contexts that led to positive and negative deprescribing outcomes.

Design: A realist evaluation using a sequential mixed methods approach, conducted alongside the EMPOWER randomised clinical trial.

Setting: Community, Quebec, Canada.

Participants: 261 older chronic benzodiazepine consumers, who received the EMPOWER intervention and had complete 6-month follow-up data.

Intervention: Mailed deprescribing brochure on benzodiazepines.

Measurements: Motivation (intent to discuss deprescribing; change in knowledge test score; change in beliefs about the risk-benefits of benzodiazepines, measured with the Beliefs about Medicines Questionnaire), capacity (self-efficacy for tapering) and opportunity (support from a physician or pharmacist).

Results: The intervention triggered the motivation to deprescribe among 167 (n=64%) participants (mean age 74.6 years±6.3, 72% women), demonstrated by improved knowledge (risk difference, 58.50% (95% CI 46.98% to 67.44%)) and increased concern about taking benzodiazepines (risk difference, 67.67% (95% CI 57.36% to 74.91%)). Those who attempted to taper exhibited increased self-efficacy (risk difference, 56.90% (95% CI 45.41% to 65.77%)). Contexts where the deprescribing mechanisms failed included lack of support from a healthcare provider, a focus on short-term quality of life, intolerance to withdrawal symptoms and perceived poor health.

Conclusion: Deprescribing mechanisms that target patient motivation and capacity to deprescribe yield successful outcomes in contexts where healthcare providers are supportive, and patients do not have internal competing desires to remain on drug therapy.

Trial registration number: ClinicalTrials.gov: NCT01148186.

Keywords: EMPOWER; benzodiazepines; deprescribing; mechanisms; realist evaluation.

Conflict of interest statement

Competing interests: None declared.

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Figures

Figure 1
Figure 1
(A) Initial deprescribing context–mechanism–outcome configuration. (B) Refined deprescribing context–mechanism–outcome configuration.

References

    1. Jansen J, Naganathan V, Carter SM, et al. . Too much medicine in older people? deprescribing through shared decision making. BMJ 2016;353:i2893.10.1136/bmj.i2893
    1. Scott IA, Hilmer SN, Reeve E, et al. . Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med 2015;175:827–34.10.1001/jamainternmed.2015.0324
    1. Frank C, Weir E. Deprescribing for older patients. CMAJ 2014;186:1369–76.10.1503/cmaj.131873
    1. Reeve E, To J, Hendrix I, et al. . Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging 2013;30:793–807.10.1007/s40266-013-0106-8
    1. Woodward MC. Deprescribing: achieving Better Health Outcomes for older people through reducing medications. J Pharm Pract Res 2003;33:323–8.10.1002/jppr2003334323
    1. Scott IA, Gray LC, Martin JH, et al. . Deciding when to stop: towards evidence-based deprescribing of drugs in older populations. Evid Based Med 2013;18:121–4.10.1136/eb-2012-100930
    1. Iyer S, Naganathan V, McLachlan AJ, et al. . Medication withdrawal trials in people aged 65 years and older: a systematic review. Drugs Aging 2008;25:1021–31.
    1. Van der Cammen TJ, Rajkumar C, Onder G, et al. . Drug cessation in complex older adults: time for action. Age Ageing 2014;43:20–5.10.1093/ageing/aft166
    1. Declercq T, Petrovic M, Azermai M, et al. . Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev 2013;3:CD007726.10.1002/14651858.CD007726.pub2
    1. Martin P, Tamblyn R, Ahmed S, et al. . A drug education tool developed for older adults changes knowledge, beliefs and risk perceptions about inappropriate benzodiazepine prescriptions in the elderly. Patient Educ Couns 2013;92:81–7.10.1016/j.pec.2013.02.016
    1. Ostini R, Hegney D, Jackson C, et al. . Systematic review of interventions to improve prescribing. Ann Pharmacother 2009;43:502–13.10.1345/aph.1L488
    1. Tannenbaum C, Martin P, Tamblyn R, et al. . Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med 2014;174:890–8.10.1001/jamainternmed.2014.949
    1. Cook JM, Biyanova T, Masci C, et al. . Older patient perspectives on long-term anxiolytic benzodiazepine use and discontinuation: a qualitative study. J Gen Intern Med 2007;22:1094–100.10.1007/s11606-007-0205-5
    1. Reeve E, Wiese MD, Hendrix I, et al. . People’s attitudes, beliefs, and experiences regarding polypharmacy and willingness to Deprescribe. J Am Geriatr Soc 2013;61:1508–14.10.1111/jgs.12418
    1. Pollmann AS, Murphy AL, Bergman JC, et al. . Deprescribing benzodiazepines and Z-drugs in community-dwelling adults: a scoping review. BMC Pharmacol Toxicol 2015;16:19.10.1186/s40360-015-0019-8
    1. Wong G, Westhorp G, Manzano A, et al. . RAMESES II reporting standards for realist evaluations. BMC Med 2016;14:96.10.1186/s12916-016-0643-1
    1. Johansson T, Abuzahra ME, Keller S, et al. . Impact of strategies to reduce polypharmacy on clinically relevant endpoints: a systematic review and meta-analysis. Br J Clin Pharmacol 2016;82:532–48.10.1111/bcp.12959
    1. Page AT, Clifford RM, Potter K, et al. . The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta-analysis. Br J Clin Pharmacol 2016;82:583–623.10.1111/bcp.12975
    1. Billioti de Gage S, Moride Y, Ducruet T, et al. . Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ 2014;349:g5205.10.1136/bmj.g5205
    1. American Geriatrics Society 2015 Updated Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2015;63:2227–46.10.1111/jgs.13702
    1. Finkle WD, Der JS, Greenland S, et al. . Risk of fractures requiring hospitalization after an initial prescription for zolpidem, alprazolam, lorazepam, or diazepam in older adults. J Am Geriatr Soc 2011;59:1883–90.10.1111/j.1532-5415.2011.03591.x
    1. Paterniti S, Dufouil C, Alpérovitch A. Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of vascular aging study. J Clin Psychopharmacol 2002;22:285–93.10.1097/00004714-200206000-00009
    1. Allain H, Bentué-Ferrer D, Polard E, et al. . Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 2005;22:749–65.10.2165/00002512-200522090-00004
    1. Cotroneo A, Gareri P, Nicoletti N, et al. . Effectiveness and safety of hypnotic drugs in the treatment of insomnia in over 70-year old people. Arch Gerontol Geriatr 2007;44:121–4.10.1016/j.archger.2007.01.018
    1. Tannenbaum C. Effect of age, education and health status on community dwelling older men’s health concerns. Aging Male 2012;15:103–8.10.3109/13685538.2011.626819
    1. Tannenbaum C, Mayo N, Ducharme F. Older women’s health priorities and perceptions of care delivery: results of the WOW health survey. CMAJ 2005;173:153–9.10.1503/cmaj.050059
    1. Anderson K, Stowasser D, Freeman C, et al. . Prescriber barriers and enablers to minimising potentially inappropriate medications in adults: a systematic review and thematic synthesis. BMJ Open 2014;4:e00654410.1136/bmjopen-2014-006544
    1. Pawson R. The science of evaluation: a realist manifestoAIA. Sage; 2013.
    1. Martin P, Tamblyn R, Ahmed S, et al. . An educational intervention to reduce the use of potentially inappropriate medications among older adults (EMPOWER study): protocol for a cluster randomized trial. Trials 2013;14:8010.1186/1745-6215-14-80
    1. Tannenbaum C, Martin P. Sedative-Hypnotic medication De-Prescribing brochure. Montréal Iudgd,2014.
    1. Hein G. Institute for inquiry constructivist learning theory. Institute for Inquiry available . 1991.
    1. Festinger L. A Theory of Social comparison processes. Human Relations 1954;7:117–40.10.1177/001872675400700202
    1. Michie S, van Stralen MM, West R. The behaviour change wheel: a new method for characterising and designing behaviour change interventions. Implement Sci 2011;6:42.10.1186/1748-5908-6-42
    1. JW C, P-C V. Designing and conducting mixed methods research. Thousand Oaks, CA: Sage Publications, 2007.
    1. Horne R, Weinman J, Hankins M. The beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 1999;14:1–24.10.1080/08870449908407311
    1. Bélanger L, Morin CM, Bastien C, et al. . Self-efficacy and compliance with benzodiazepine taper in older adults with chronic insomnia. Health Psychol 2005;24:281–7.10.1037/0278-6133.24.3.281
    1. McDowell I. Measuring health: a guide to rating scales and questionnaires. 3rd ed New York, NY: Oxford University Press; US, 2006.
    1. Sandelowski M. Combining qualitative and quantitative sampling, data collection, and analysis techniques in mixed-method studies. Res Nurs Health 2000;23:246–55.10.1002/1098-240X(200006)23:3<246::AID-NUR9>;2-H
    1. Ellis P. The Essential Guide to effect sizes: statistical Power, Meta-Analysis, and the interpretation of Research results. Cambridge: Cambridge University Press, 2010.
    1. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101.10.1191/1478088706qp063oa
    1. O’Cathain A, Murphy E, Nicholl J. Three techniques for integrating data in mixed methods studies. BMJ 2010;341:c4587.10.1136/bmj.c4587
    1. Farmer T, Robinson K, Elliott SJ, et al. . Developing and implementing a triangulation protocol for qualitative health research. Qual Health Res 2006;16:377–94.10.1177/1049732305285708
    1. Prochaska J. Transtheoretical Model of Behavior Change : Gellman M, Turner JR, Encyclopedia of behavioral medicine New York NY: Springer, 2013.
    1. West R. Time for a change: putting the transtheoretical (Stages of Change) Model to rest. Addiction 2005;100:1036–9.10.1111/j.1360-0443.2005.01139.x
    1. Cassel CK, Guest JA. Choosing wisely: helping physicians and patients make smart decisions about their care. JAMA 2012;307:1801–2.10.1001/jama.2012.476
    1. Sunny C, McDonald DW, Landay JA. Theory-driven design strategies for technologies that support behavior change in everyday life. New York NY: ACM.
    1. Johnson B, Christensen LB. Educational research: quantitative, qualitative, and mixed approaches. 5th ed, 2014.
    1. Hilmer SN, Gnjidic D, Le Couteur DG. Thinking through the medication list - appropriate prescribing and deprescribing in robust and frail older patients. Aust Fam Physician 2012;41:924.
    1. Holmes HM, Todd A. Evidence-based deprescribing of statins in patients with advanced illness. JAMA Intern Med 2015;175:701–2.10.1001/jamainternmed.2015.0328
    1. Bem DJ. Self-perception: an alternative interpretation of cognitive dissonance phenomena. Psychol Rev 1967;74:183–200.’10.1037/h0024835
    1. Dalkin SM, Greenhalgh J, Jones D, et al. . What’s in a mechanism? development of a key concept in realist evaluation. Implement Sci 2015;10:49.10.1186/s13012-015-0237-x
    1. Pawson R, Tilley N. Realistic evaluation. London: SAGE, 1997.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel